What Is Familial Hypercholesterolemia?

Familial hypercholesterolemia (FH) is an inherited condition that causes dangerously high levels of LDL cholesterol from birth, dramatically raising the risk of early heart disease. It affects roughly 1 in 200 to 300 people worldwide, making it one of the most common genetic disorders on the planet, yet the vast majority of people who have it don’t know it.¹ Because FH silently accelerates artery damage decades before symptoms appear, understanding how it works, how it’s found, and what can be done about it is genuinely life-saving information.

What Goes Wrong in the Body

Under normal circumstances, your liver clears LDL particles from the bloodstream using a surface protein called the LDL receptor. In FH, a genetic mutation cripples that process. The most common culprit is a defect in the gene for the LDL receptor itself (LDLR), but mutations in two other genes, APOB and PCSK9, can produce the same result.² In all three cases, LDL particles pile up in the blood because the liver can’t pull them out efficiently. That surplus cholesterol infiltrates artery walls, building plaques that narrow and harden vessels years or decades earlier than they otherwise would.

The severity depends on how many faulty gene copies you carry. People with one affected copy (heterozygous FH) have LDL levels roughly two to three times the normal range and face a significantly elevated risk of heart attack, often before age 55. People who inherit mutations on both copies (homozygous FH) are in a far more dangerous position: their LDL can soar to extreme levels, and cardiovascular disease often appears in childhood or adolescence.³ Homozygous FH is rare, but heterozygous FH is strikingly common for a single-gene disorder.

How Common It Is and Why So Few People Know

Estimates of FH prevalence have tightened over the years. A recent expert consensus from the National Lipid Association puts the global figure at about 1 in 311.⁴ Other large analyses estimate 1 in 200 to 250, depending on the population and diagnostic criteria used.⁵ That means millions of people worldwide carry a mutation, and FH cuts across every race and ethnicity.

Despite that prevalence, only about 10% of people with FH have been diagnosed and adequately treated.⁶ The diagnosis gap exists partly because high cholesterol in a young person is often dismissed as a lifestyle problem or not checked at all. Many clinicians don’t think to ask whether a patient’s family has a pattern of early heart attacks, and routine cholesterol screenings in childhood are far from universal. The result is a condition that could be caught early and managed effectively but instead goes unnoticed until someone has a cardiac event.

Physical Signs That Can Hint at FH

Most people with heterozygous FH look and feel perfectly healthy for years. But there are a few visible clues that, when present, strongly suggest the condition. The most specific is a tendon xanthoma: a hard, painless lump that forms along tendons, especially the Achilles tendon or the tendons on the back of the hand. These lumps are cholesterol deposits, and their presence in a person with high LDL is considered near-diagnostic.⁷

Two other signs are associated with FH but are less specific on their own. Corneal arcus, a whitish-gray ring around the iris, can signal abnormal lipid levels when it appears in someone under 45. Xanthelasma, yellowish deposits on the skin around the eyelids, is perhaps more widely recognized but occurs in people without FH too.⁸ In homozygous FH, cholesterol deposits can appear much earlier and more dramatically, sometimes even in childhood. Case reports describe teenagers with eruptive xanthomas covering the skin alongside corneal arcus.⁹ In the homozygous form, cardiovascular disease itself, including narrowing of the aortic valve and accelerated plaque buildup, often shows up in the first two decades of life.¹⁰

How FH Is Diagnosed

Several clinical scoring systems exist to identify FH without genetic testing. The most commonly used are the Dutch Lipid Clinic Network criteria, the Simon Broome Register criteria from the UK, and the US MedPed Program.¹¹ These tools combine LDL cholesterol levels, physical signs like tendon xanthomas, and family history of early heart disease to generate a probability score. They’re useful, especially in settings where genetic testing isn’t readily available, but they all have limitations, particularly in populations where the specific LDL thresholds or family history patterns don’t quite fit the criteria they were designed around.

Genetic testing offers a more definitive answer. A panel that sequences the LDLR, APOB, and PCSK9 genes can confirm a diagnosis and identify the specific mutation, which matters both for prognosis and for screening family members. Expert panels now recommend genetic testing as the standard of care for people with definite or probable FH based on clinical criteria, and for their at-risk relatives.¹² That said, a negative genetic test doesn’t entirely rule FH out; some mutations are in regions of the gene that standard panels don’t cover, and the field continues to discover new variants. A Russian study cataloging FH mutations, for instance, found that over a third of the variants identified in their population had never been reported elsewhere.¹³

Why Monogenic FH Matters More Than High Cholesterol Alone

Not all severely elevated LDL stems from a single-gene defect. Some people have a “polygenic” form of high cholesterol, meaning many small genetic nudges, combined with lifestyle factors, push their LDL high without a single broken gene. The distinction matters for risk. A large study comparing the two groups found that people with monogenic FH had a meaningfully higher risk of cardiovascular disease than those with polygenic high cholesterol, even when their LDL levels were similar at the time they entered the study.¹⁴ That finding suggests that the cumulative burden of sky-high LDL from birth, which is what a monogenic mutation causes, inflicts vascular damage beyond what a snapshot cholesterol reading can capture.

This distinction also shapes treatment decisions. Someone whose high LDL responds well to diet changes and a moderate statin dose may have the polygenic type. Someone whose LDL barely budges despite aggressive medication is more likely to carry a monogenic mutation and may need additional therapies, including some of the newer options discussed below.¹⁵

First-Line Treatment With Statins and Ezetimibe

Statins remain the backbone of FH treatment. By blocking an enzyme the liver uses to manufacture cholesterol, statins force the liver to pull more LDL out of the bloodstream, which is exactly the process that FH impairs. For people with heterozygous FH, high-dose statin therapy combined with ezetimibe, a drug that blocks cholesterol absorption in the gut, is now standard practice and can push LDL close to normal levels.¹⁶

The evidence for starting treatment early is strong. In children and adolescents with heterozygous FH, a meta-analysis of randomized trials found that statins reduced LDL by about 34% compared to placebo, and adding ezetimibe cut it by an additional 16%.¹⁷ A trial specifically testing the combination of ezetimibe and simvastatin in adolescents showed LDL reductions approaching 50% at six weeks and holding near 49% out to one year.¹⁸ Starting these drugs in childhood or adolescence reduces the total years of exposure to extreme LDL, which is the fundamental driver of arterial damage in FH.

PCSK9 Inhibitors and Newer Therapies

For patients who don’t reach safe LDL levels on statins and ezetimibe alone, a class of injectable drugs called PCSK9 inhibitors has transformed treatment over the past decade. PCSK9 is a protein that tags LDL receptors for destruction; by blocking it, these drugs let whatever functional LDL receptors a person has work harder and last longer. The two currently used PCSK9 inhibitors, alirocumab and evolocumab, lower LDL by anywhere from about 30% to 70% depending on the dose and the patient population.¹⁹ Real-world data from Italy showed that patients with heterozygous FH sustained roughly a 59% reduction in LDL over two years on these drugs, and even patients with homozygous FH, who have far fewer functional receptors, achieved a similar percentage reduction.²⁰

In pediatric patients, a pooled analysis of evolocumab and alirocumab showed LDL reductions of about 38%, along with meaningful drops in apolipoprotein B and lipoprotein(a), another particle linked to cardiovascular risk.²¹ These drugs are given as an injection every two to four weeks, which is a drawback for some patients.

A newer approach uses a small interfering RNA molecule called inclisiran, which silences the gene responsible for making PCSK9 in the liver. The practical advantage is dosing: inclisiran requires only two or three injections per year while producing LDL-lowering effects comparable to the monoclonal antibody PCSK9 inhibitors.²² For people with homozygous FH who may have almost no functional LDL receptors at all, PCSK9-targeted drugs are less effective because there aren’t enough receptors to rescue. That gap drove the development of evinacumab, a monoclonal antibody that targets a completely different pathway involving a protein called ANGPTL3. It produces substantial LDL lowering even in patients who don’t respond to other drugs.²³

Lipoprotein Apheresis for the Hardest-to-Treat Cases

When drugs alone aren’t enough, lipoprotein apheresis offers a mechanical solution. The procedure works a bit like dialysis: blood is drawn, passed through a device that selectively removes LDL particles, and returned to the patient. A single session can cut LDL by roughly 60% or more, though levels gradually climb back between treatments, so sessions are typically repeated every one to two weeks.²⁴ Apheresis remains the gold standard therapy for homozygous FH, particularly when started early in childhood and combined with lipid-lowering medication.²⁵

The burden of regular apheresis sessions is significant. Patients need to visit a treatment center every week or two, and each session takes a few hours. Still, for children with homozygous FH whose LDL can start at levels above 500 mg/dL, apheresis can mean the difference between aggressive cardiovascular disease in adolescence and a relatively stable trajectory into adulthood.

Finding Families Through Cascade Screening

Because FH follows predictable inheritance patterns, identifying one case in a family opens the door to catching it in relatives before damage accumulates. Cascade screening involves testing the close family members of a diagnosed patient, typically starting with parents, siblings, and children, using either a lipid panel, genetic testing, or both. This approach is cost-effective by any standard measure. A systematic review found that cascade screening was cost-effective in about 78% of the economic analyses that evaluated it.²⁶

A US simulation analysis dug into the specifics and found that cascade genetic testing of first-degree relatives was cost-effective when started at any age from 5 through 35, at less than $50,000 per life year gained. Starting after age 40 pushed costs above that threshold, and the benefit in life years gained per person was smaller. For second-degree relatives like aunts, uncles, and grandparents, cascade testing was cost-effective when initiated around age 10, but the economic case was weaker at other ages.²⁷ The takeaway is clear: the earlier you test relatives, the more value you get out of it.

Universal childhood cholesterol screening, rather than testing only children with a known family history, has also been studied. One program found that most children referred from a national screening database who had elevated cholesterol turned out to have genetically confirmed FH, suggesting that family history alone misses too many cases.²⁸ Not every country has adopted this approach, but the evidence favoring early detection keeps growing.

FH During Pregnancy

Pregnancy presents a specific management challenge. Statins and most other lipid-lowering drugs are not considered safe during pregnancy and breastfeeding. Guidelines recommend that women with FH receive pre-pregnancy counseling and stop lipid-lowering therapy at least four weeks before trying to conceive.²⁹ That leaves a treatment gap of many months during which LDL can spike. Bile acid sequestrants like cholestyramine or colesevelam, which aren’t absorbed into the bloodstream, are sometimes used during pregnancy as a partial substitute.

For women with severe FH, especially those with a prior history of cardiovascular events, LDL apheresis during pregnancy has been documented as safe and effective. A case report described a woman with FH and a previous heart attack who underwent 16 apheresis sessions during pregnancy, performed every two weeks, achieving a 60% LDL reduction and maintaining stable lipid levels throughout.³⁰ This level of intervention isn’t necessary for most pregnant women with FH, but it illustrates how high the stakes can be and how aggressive management sometimes needs to get.

The Role of Diet and Lifestyle

No amount of dietary change can replace medication in FH, but diet does make a measurable difference on top of drugs. A systematic review of dietary interventions in children and adolescents with FH found that plant sterols, at doses between about 1.2 and 2.8 grams per day, produced LDL reductions of 10% to 18% beyond what control groups achieved. Dietary counseling interventions ranged more widely, with LDL reductions from about 3% to 22% depending on the specifics. Even modifying the type of fat consumed showed an effect: switching to rapeseed oil, which is high in monounsaturated fat, reduced LDL by about 7%.³¹ These aren’t dramatic numbers in isolation, but in a condition where every point of LDL reduction matters and treatment extends over a lifetime, stacking dietary strategies on top of medication adds up.

The Psychological Side of a Lifelong Diagnosis

Living with FH means taking medication every day, often starting in childhood, for a condition that produces no symptoms until something goes wrong. That disconnect between feeling fine and being told your arteries are at risk makes adherence genuinely difficult. Research confirms that many FH patients fall short of full treatment adherence, and the barriers aren’t just about forgetting pills. Beliefs about medication, perceptions of how serious the disease is, and concerns about side effects all influence whether someone sticks with therapy.³²

Diet and exercise matter for FH too, but adopting and maintaining those behaviors faces its own obstacles. A review of the psychological research in this area found that adherence to both pharmacological and lifestyle therapies is broadly sub-optimal among FH patients, and that behavior-change interventions targeting the specific psychological barriers are needed.³³ This is an area where family support, clear communication from clinicians, and practical strategies like simplified dosing schedules can make real differences in outcomes.

How the LDL Receptor Changed Medicine

The story of FH is inseparable from the discovery of the LDL receptor itself, work that earned Michael Brown and Joseph Goldstein the Nobel Prize in 1985. Their research on families with FH revealed not just why these patients had dangerously high cholesterol, but introduced fundamental concepts to cell biology: the idea that cells use specific receptors to pull molecules inside, that those receptors are recycled back to the surface for reuse, and that cells regulate how many receptors they display based on internal signals.³⁴ Those discoveries laid the groundwork for the development of statins and, eventually, every targeted therapy that followed. FH was, in a sense, the disease that taught medicine how cholesterol metabolism works, and every treatment option available today traces back to what researchers learned from studying families with this condition.